Vanderbilt-Emory-Cornell-Duke Global Health Fellowship Consortium-Expanding Diversity for Global Equity (EDGE)

项目概要-PANEL应用 范德比尔特-埃默里-康奈尔-杜克全球卫生研究员联盟（VECDor）由以下机构组成： 与非洲主要LMIC研究机构（埃塞俄比亚，加纳，肯尼亚， 莫桑比克、尼日利亚、卢旺达、坦桑尼亚和赞比亚）、亚洲（印度和越南）、中美洲 （危地马拉、洪都拉斯和尼加拉瓜）和加勒比（海地）。VECDor的集体研究组合 包括传染性和非传染性疾病的各种不同和互补的重点， 在非传染性疾病和艾滋病毒/结核病方面具有特别的优势。VECDor机构和教师带来了大量的调查 成功支持87名高效的VECDor，证明了这一点 研究员和学者在2012-2017年，其中许多人现在有R或K或类似的职业发展赠款， 自己的.我们高效的支持中心经过10多年的Fogarty学者和研究员研究的磨练 培训管理，并最大限度地增加研究培训资金的流动。2017-2022年，我们将继续 利用多种财政和实物共同资助来源，并与多个机构和NIH资助的 培训计划，并与少数民族机构合作伙伴梅哈里医学院选择和部署80， 100名美国和LMIC学员，他们对全球健康研究事业有着杰出的承诺。我们正在创新， 加强联盟领导层的多样性，增加和扩大中环的战略培训地点 美国，越南和西非，以及增加NCD研究机会。我们将加强我们的 在实地部署之前，在自愿幼儿发展机构增加有针对性的短期培训讲习班，从而实施辅导计划; 招募有成就的VECDor校友为学员提供咨询;并提供奖学金后的培训 写作和职业指导，以优化学术产出的质量和学员在获得研究方面的成功 以及职业发展赠款和职位。研究主题将涉及所有主题和地理区域 感兴趣的学员和赞助NIH研究所和中心。我们将继续记录影响， * 建立监测和评价工具，成功跟踪所有人的职业轨迹和产出 学员，并将进一步完善我们的网络工具，以分享知识，促进地方和全球网络， 加强和维持VECDor学员和校友的临床研究技能。VECDor基于 合作伙伴之间相互尊重和建设性的关系，我们的研究创新的集体记录 和指导，并与我们的LMIC合作伙伴机构成功的能力建设。结合我们广泛的 在研究培训项目管理方面的经验，在具有全球意义的疾病方面的强大研究资金， 著名的国际研究培训合作伙伴和网站，以及持续的机构杠杆作用，VECDor将 继续培养世纪的全球健康研究领袖。

PROJECT SUMMARY – PARENT APPLICATION The Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor) comprises institutions with decades-long global partnerships with premier LMIC research institutions in Africa (Ethiopia, Ghana, Kenya, Mozambique, Nigeria, Rwanda, Tanzania, and Zambia), Asia (India and Vietnam), Central America (Guatemala, Honduras, and Nicaragua), and the Caribbean (Haiti). VECDor's collective research portfolio encompasses diverse and complementary foci in both communicable and non-communicable diseases (NCDs), with particular strengths in NCDs and HIV/TB. VECDor institutions and faculty bring substantial investigative accomplishment and mentoring excellence, evidenced by successfully supporting 87 highly productive VECDor Fellows and Scholars in 2012-2017, many of whom now have R or K or similar career development grants of their own. Our efficient support center has been honed over 10 years of Fogarty Scholars and Fellows research training administration, and maximizes the flow of funds for research training. In 2017-2022, we will continue to leverage multiple sources of financial and in-kind co-funding and link with multiple institutional and NIH-funded training programs and with minority institution partner Meharry Medical College to select and deploy 80 to 100 US and LMIC trainees with outstanding promise for global health research careers. We are innovating by enhancing diversity in the consortium's leadership, adding and expanding strategic training sites in Central America, Vietnam, and West Africa, and increasing NCD research opportunities. We will enhance our mentorship plan by adding tailored short-term training workshops at VECD institutions before field deployment; enlisting accomplished VECDor alumni in trainee advising; and providing post-fellowship training in grant writing and career coaching, to optimize the quality of scholarly output and trainee success in obtaining research and career development grants and positions. Research themes will address all topic and geographical areas of interest to trainees and sponsoring NIH Institutes and Centers. We will continue to document impacts with our established monitoring and evaluation tools that successfully track the career trajectories and outputs of all trainees, and will further refine our web-based tools to share knowledge, foster local and global networking, and strengthen and sustain clinical research skills among VECDor trainees and alumni. VECDor is built on mutually respectful and constructive relationships among its partners, our collective record of research innovation and mentorship, and successful capacity building with our LMIC partner institutions. Combining our extensive experience in research training program management, robust research funding in diseases of global significance, renowned international research training partners and sites, and sustained institutional leveraging, VECDor will continue to nurture global health research leaders of the 21st century.